LOGOGRAM: Validation of Allergy Care Flowcharts in Primary Care: Experience From Occitanie
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Implementation of an innovative tool based around AI-automated decision trees on an application.
- Who it may be relevant to
- Registry conditions: Allergy. Basic parameters: from 1 year · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Validation Des Diagrammes de Flux d'Allergies en Soins Primaires : expérience de la région Occitanie
Overview
This study, aimed at validating decision trees developed through collaboration between general practitioners and allergists, seeks to provide French data to optimize care pathways for patients with allergic diseases from the primary care level and to reduce the delays and negative consequences associated with incorrect diagnoses. Most patients with allergic conditions are initially seen in primary care, often during exacerbations. Although allergies, in their many clinical forms, account for approximately 6-8% of primary care consultations, clinicians frequently receive little or no formal training in this field and may not be fully aware of the latest evidence, associated risks, or appropriate referral pathways. These gaps can significantly affect the quality of care and patients' quality of life, while also contributing to higher morbidity and mortality. In this context, the European Academy of Allergy and Clinical Immunology established a multidisciplinary task force to transform existing allergy guidelines into simple, practical, and accessible tools to facilitate diagnosis and management in primary care. The group developed five decision trees covering asthma, anaphylaxis, drug allergy, food allergy, rhinitis, and urticaria to support primary care physicians and other non-specialists in managing patients with symptoms suggestive of allergic or hypersensitivity reactions. The results of this project will be directly applicable to the daily clinical practice of general practitioners in France and could serve as a model for replication in other regions and countries, although adaptations may be required depending on national healthcare systems.
Interventions
- Other Implementation of an innovative tool based around AI-automated decision trees on an application
The application provides immediate access to the algorithms (decision trees). Investigators can access a dedicated interface and enter participant data, including the suspected diagnosis, symptoms, acute episode or history of allergic disease, and the medical decision made (diagnosis, therapeutic management, or referral to a specialist). Management options based on the five algorithms are then generated to support physicians in the diagnosis and management of allergic diseases.
Primary outcome measures
- Rate of referral to allergy specialists following primary care consultations for allergic diseases [Time frame: through study completion, an average of 4 years]
Secondary outcome measures (1)
- Ease of use of the clinical decision trees [Time frame: through study completion, an average of 4 years]
Eligibility criteria
Inclusion criteria
- Patients with suspected asthma, anaphylaxis, drug allergy, food allergy, rhinitis and urticaria.
- Patients aged 1 year or older at inclusion, registered with a health insurance plan.
- Patient or legal representative of the minor patient who agrees to participate in the research.
Exclusion criteria
- Adults placed under guardianship or curatorship.
- Patients already followed by an allergist and/or a specialist doctor for their allergies.
- Patients who participate in a clinical research study relating to an antiallergic medication, immunosuppressant, immunomodulator in the year preceding their consultation visit with the GP.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Non-randomized
- Model
- Sequential
- Masking
- Open label
- Primary purpose
- Diagnostic
Study locations
France · 10 centers
- Msp Espace Sante Servian — Béziers
- MSP Universitaire Avicenne — Cabestany
- Msp Montpellier -Cevenne — Montpellier
- Msp Narbo Ouest — Narbonne
- Msp Charles Gide — Nîmes
- Msp Beau Art — Perpignan
- MSP Calypso — Roujan
- Département Universitaire de Médecine Générale MSPU CHU Montpellier — Saint-Georges-dOrques
- … and 2 more centers
Identifiers
NCT: NCT07631039 · RECHMPL23_0327 · 2025-A02183-46